BioNTech
BNTX
80.96
-0.42
-0.52%
BioNTech
US · BNTX
#801 by market cap
Listed 2019
80.96
-0.42
-0.52%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
A Quick Look at Today's Ratings for BioNTech(BNTX.US), With a Forecast Between $125 to $132Market Newswire · 2026/11/5
-
Rating change
H.C. Wainwright Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $110Market Newswire · 2026/11/10
-
Rating change
H.C. Wainwright Maintains BioNTech(BNTX.US) With Buy Rating, Cuts Target Price to $110Market Newswire · 2026/11/9
-
Rating change
BioNTech Price Target Cut to $106.00/Share From $114.00 by Morgan StanleyDow Jones · 2026/11/5
-
Rating change
Goldman Sachs Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $127Market Newswire · 2026/11/6
-
Rating change
BioNTech Is Maintained at Overweight by Morgan StanleyDow Jones · 2026/11/5
-
Rating change
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $106Market Newswire · 2026/11/9
-
Rating change
BioNTech Is Maintained at Buy by UBSDow Jones · 2026/11/5
-
Rating change
HC Wainwright & Co. Maintains Buy on BioNTech, Lowers Price Target to $110Benzinga · 2026/11/9
-
Citi Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $125Market Newswire · 2026/11/11
-
J.P. Morgan Maintains BioNTech(BNTX.US) With Hold Rating, Announces Target Price $93Market Newswire · 2026/11/19
-
Company notice
BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)SEC · 2026/10/26
-
Company notice
BioNTech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]SEC · 2026/11/10
-
BioNTech May Be the Next Moderna. Even If It Isn't, the Stock Is a Buy. -- Barrons.comBarron's · 2026/11/12
-
BofA Securities Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $108Market Newswire · 2026/11/17
-
Company notice
BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)SEC · 2026/11/3
-
Rating change
BioNTech Price Target Raised to $93.00/Share From $92.00 by JP MorganDow Jones · 2026/11/20
-
Company notice
BioNTech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]SEC · 2026/10/26
-
Company notice
BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)SEC · 2026/11/3
-
BioNTech Is Maintained at Neutral by JP MorganDow Jones · 2026/11/20
-
Rating change
BioNTech Price Target Cut to $125.00/Share From $140.00 by Wells FargoDow Jones · 2026/11/4
-
Rating change
Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $106Benzinga · 2026/11/5
-
Revenue Beat: BioNTech SE Exceeded Revenue Forecasts By 24% And Analysts Are Updating Their EstimatesSimply Wall St · 2026/11/5
-
Wells Fargo Maintains Overweight on BioNTech, Lowers Price Target to $125Benzinga · 2026/11/4
-
Rating change
Evercore ISI Group Maintains Outperform on BioNTech, Lowers Price Target to $110Benzinga · 2026/11/4
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
BioNTech discussion 0 comments